Success Metrics

Clinical Success Rate

81.8%

Based on 9 completed trials

Completion Rate

82%(9/11)

Active Trials

0(0%)

Results Posted

11%(1 trials)

Terminated

2(15%)

Phase Distribution

Ph phase_1

31%

Ph phase_2

54%

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 1Safety & dosage

4(33.3%)

Phase 2Efficacy & side effects

7(58.3%)

Phase 3Large-scale testing

1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Terminated(3)

Other(1)

Detailed Status

Completed9

Terminated2

Withdrawn1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

81.8%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (33.3%)

Phase 27 (58.3%)

Phase 31 (8.3%)

Trials by Status

terminated215%

withdrawn18%

completed969%

unknown18%

Recent Activity

0 active trials

Showing 5 of 13

completedphase_2

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

NCT00471887

completedphase_2

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

NCT00257205

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT00471887Phase 2

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Completed

NCT01034787Phase 2

Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

Completed

NCT01334099Phase 1

Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients

Terminated

NCT00488995Phase 2

Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

Withdrawn

NCT00257205Phase 3

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Completed

NCT00254579Phase 2

Study of CP-675,206 in Refractory Melanoma

Completed

NCT00313794Phase 2

Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

Completed

NCT00312975Phase 2

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Completed

NCT00431275Phase 1

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Completed

NCT00372853Phase 1

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Completed

NCT00585000Phase 1

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Terminated

NCT00086489Phase 2

CP-675,206 In Patients With Advanced Melanoma

Completed

NCT00584493

Treatment Use Study for Advanced Melanoma.

Unknown

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13